MX2007011174A - Metodos y formulaciones de metformina para tratar constipacion cronica. - Google Patents

Metodos y formulaciones de metformina para tratar constipacion cronica.

Info

Publication number
MX2007011174A
MX2007011174A MX2007011174A MX2007011174A MX2007011174A MX 2007011174 A MX2007011174 A MX 2007011174A MX 2007011174 A MX2007011174 A MX 2007011174A MX 2007011174 A MX2007011174 A MX 2007011174A MX 2007011174 A MX2007011174 A MX 2007011174A
Authority
MX
Mexico
Prior art keywords
metformin
methods
formulations
treating chronic
chronic constipation
Prior art date
Application number
MX2007011174A
Other languages
English (en)
Spanish (es)
Inventor
John Devane
Original Assignee
Agi Therapeutics Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agi Therapeutics Res Ltd filed Critical Agi Therapeutics Res Ltd
Publication of MX2007011174A publication Critical patent/MX2007011174A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2007011174A 2005-03-18 2006-03-16 Metodos y formulaciones de metformina para tratar constipacion cronica. MX2007011174A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66292005P 2005-03-18 2005-03-18
PCT/IB2006/002233 WO2007007189A2 (en) 2005-03-18 2006-03-16 Metformin methods and formulations for treating chronic constipation

Publications (1)

Publication Number Publication Date
MX2007011174A true MX2007011174A (es) 2008-02-11

Family

ID=37637555

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007011174A MX2007011174A (es) 2005-03-18 2006-03-16 Metodos y formulaciones de metformina para tratar constipacion cronica.

Country Status (10)

Country Link
US (1) US20060222709A1 (enExample)
EP (1) EP1865939A2 (enExample)
JP (1) JP2008533127A (enExample)
AU (1) AU2006268003A1 (enExample)
CA (1) CA2599531A1 (enExample)
IL (1) IL185652A0 (enExample)
MX (1) MX2007011174A (enExample)
NO (1) NO20075344L (enExample)
WO (1) WO2007007189A2 (enExample)
ZA (1) ZA200707325B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062861A2 (en) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
WO2014011926A1 (en) * 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) * 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11759441B2 (en) * 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
PT2661266T (pt) * 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
EP2599789A1 (en) 2011-12-01 2013-06-05 Bergen Teknologioverføring AS Marker and method for diagnosing diarrhea syndrome
CN104349773A (zh) * 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
CN110693868A (zh) * 2012-01-06 2020-01-17 埃尔舍利克斯治疗公司 双胍组合物和治疗代谢性病症的方法
HK1212222A1 (en) * 2012-08-29 2016-06-10 Salix Pharmaceuticals, Inc. Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
EP4410380A3 (en) * 2013-01-05 2024-10-23 Anji Pharmaceuticals Inc. Delayed-release composition comprising biguanide
CN104434846A (zh) * 2014-11-17 2015-03-25 中国药科大学 盐酸二甲双胍肠溶缓释微丸及其制备方法
TW201938147A (zh) * 2017-12-18 2019-10-01 德商拜耳廠股份有限公司 阿卡波糖與甲福明之固定劑量組合錠劑配製物及其製法
US12351847B2 (en) 2019-10-16 2025-07-08 Bayer Aktiengesellschaft Methods for the improved formation of acarbose
EP4615423A1 (en) 2022-11-07 2025-09-17 Rejuvenate Biomed NV Metformin minitablets
CN119499228A (zh) * 2023-08-22 2025-02-25 雅研(天津)生物医药科技中心(有限合伙) 盐酸二甲双胍肠溶制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1203846C (zh) * 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
TR200101333T2 (tr) * 1998-11-12 2001-10-22 Smithkline Beecham P.L.C. Bir ensülin sensitizörü ve başka bir anti-diyabetik maddenin değiştirilmiş salımı için farmasötik terkip.
US6676966B1 (en) * 2000-05-09 2004-01-13 Intellipharmaceutics Corp. Extended release metformin hydrochloride formulations
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Also Published As

Publication number Publication date
CA2599531A1 (en) 2007-01-18
IL185652A0 (en) 2008-01-06
WO2007007189A3 (en) 2007-04-26
NO20075344L (no) 2007-10-18
US20060222709A1 (en) 2006-10-05
WO2007007189A2 (en) 2007-01-18
EP1865939A2 (en) 2007-12-19
AU2006268003A1 (en) 2007-01-18
ZA200707325B (en) 2009-03-25
JP2008533127A (ja) 2008-08-21

Similar Documents

Publication Publication Date Title
MX2007011174A (es) Metodos y formulaciones de metformina para tratar constipacion cronica.
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
WO2004098589A8 (en) 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
WO2008144269A3 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
WO2007092469A3 (en) Combination of organic compounds
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
NO20075393L (no) Akarbosebaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2006071775A3 (en) Novel compounds useful for bradykinin b1 receptor antagonism
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
WO2006125178A3 (en) Tricyclic pyridazine compounds and their uses as therapeutic agents
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
WO2007120930A3 (en) Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
WO2008065144A3 (en) Galenic formulations of organic compounds
WO2006079077A3 (en) Use of diltiazem or analogs thereof as modulators of ghrelin receptor
WO2009061445A3 (en) Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction

Legal Events

Date Code Title Description
FA Abandonment or withdrawal